A retrospective study found that combining a thymoma with a three-millimeter rim of surrounding tissue on CT scans improved ...

A new commentary on efgartigimod in generalized myasthenia gravis warns that post-operative myasthenic crisis is too often ...

Looking beyond near-term headwinds paints a fairly bright picture of Johnson & Johnson’s outlook.

I am currently in the middle of moving out to live on my own.I'm sorting through my belongings while working and keeping an ...

INTerpath-001 data to be presented in Presidential Symposium, featuring the first Phase 3 results for investigational intismeran autogene plus KEYTRUDA ® (pembrolizumab), demonstrating improvements in ...

Leonard Dragone, MD, PhD, Disease Area Leader at Johnson & Johnson, discusses how nipocalimab is being incorporated into generalized MG care, what long-term data show, and where J&J sees the therapy’s ...

The FDA has approved an autoinjector formulation of Zilbrysq, a complement inhibitor for the treatment of generalized myasthenia gravis.

(Adnkronos) - "I'm here at Gemelli, I say it smiling because I don't want to make it a tragic thing, for an operation". This is how the video shared on social media by Antonella Elia begins, as she ...

In the end, over 200 young people were stopped, mostly - over 80% - minors. After 48 hours of very high tension, today Prime Minister Giorgia Meloni convenes a meeting on public order tomorrow.

Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatment Optional reduction of infusion time for 350 mg dose to 15 to 30 ...

For the second straight quarter, the cardiovascular unit experienced slower sales growth due to ongoing struggles in the ...

Johnson & Johnson reported third-quarter 2026 adjusted earnings and revenue that edged past Wall Street expectations, but the ...